L&C Bio financials at a glance

+ Portfolio

The revenue of L&C Bio is reported as 68.86955 billion Won in the fiscal year 2023. The earnings were 2096 Won per share in 2023, which was 219.51 higher than 2021. And about 10.49704 billion Won are reported as free cash flow in the financials of L&C Bio 2023. Dividends of 50 Won per share were paid to shareholders of L&C Bio stock KOSDAQ:A290650 in fiscal 2023.

₩68.87B

Revenue

₩2.10k

Earnings Per Share

50.49%

Gross Margin %

₩19.60B

Free Cash Flow

Revenue

68,869.55

Earnings Per Share

2,096.00

Gross Margin %

50.49

Free Cash Flow

19,600.00

Financials

Year	Year	TTM	2023	2021	2020	2019	2018
Rev.	Revenue	N/A	₩68.87B	₩45.68B	₩32.97B	₩29.15B	₩21.24B
GM %	Gross Margin %	51.59%	50.49%	62.29%	59.32%	64.02%	63.00%
OM	Operating Margin	17.12%	11.25%	28.83%	22.21%	30.98%	25.79%
EPS	Earnings Per Share	₩2.36k	₩2.10k	₩656.00	₩494.00	₩324.00	₩271.00
Div.	Dividends	N/A	₩50.00	₩50.00	₩50.00	₩0.00	₩0.00
PR %	Payout Ratio %	0	2.39%	7.62%	10.12%	0	0
Sha.	Shares	N/AM	22.68M	22.68M	21.88M	22.08M	21.7M
OCF	Operating Cash Flow	N/A	₩35.00B	₩11.12B	₩7.42B	₩6.43B	₩3.85B
FCF	Free Cash Flow	N/A	₩19.60B	₩583.88M	₩4.40B	₩4.47B	₩-,893.38M
FCFS	Free Cash Flow Per Share	₩-,448.04	₩-1,633.55	₩-21.58	₩199.32	₩605.71	₩-,146.90

L&C Bio financials at a glance

Financials

Discover